Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Ring finger protein 11 (RNF11)
- Target
- RNF11
- Molecular classification
- E3 ubiquitin-protein ligase ("RING finger protein" places it in the RING-type E3 ligases), Adapter protein for HECT E3 ligases, Other: Ubiquitination-related protein
01
Overview
Ring finger protein 11 (RNF11) is a small, 154-amino-acid protein containing a canonical RING-H2 finger motif critical for mediating protein-protein interactions and E3 ubiquitin ligase activity.[1][2][3] RNF11 acts as a regulator and modulator of other E3 ligases, especially the NEDD4 family of HECT-type ligases, influencing substrate selection and stability through ubiquitin-mediated degradation. This makes RNF11 a central player in diverse signaling pathways, including TGF-β, NF-κB, and EGFR, thereby controlling processes such as inflammation, cell growth, and endosomal sorting. It is implicated in diseases like cancer and neurodegenerative disorders, where its overexpression or dysregulation alters key cellular processes.[1][2][3]
- Other names
- RNF11Ring finger protein 11CGI-123SID1669Sid1669pMGC51169
02
Mechanism of action
Not established for direct targeting, but mechanistic roles for modulation include: Inhibition of ubiquitin ligase activity; Blocking protein-protein interactions within E3 ligase complexes; Modulation of downstream signaling pathways (e.g., NF-κB, TGF-β).
03
Biological functions
Ubiquitin-mediated protein degradationRegulation of TGF-β (transforming growth factor beta) signalingRegulation of EGFR (epidermal growth factor receptor) traffickingNegative and positive regulation of NF-κB signaling (inflammatory signaling termination)Protein-protein interactionsRegulation of type I interferon signaling (innate antiviral response)Modulation of endosomal trafficking
04
Disease associations
Cancer (implicated in tumorigenesis, invasion, metastasis, and often overexpressed in tumors)Neurodegenerative disease (altered regulation associated with neuroinflammation and pathogenesis)Multiple endocrine neoplasia (MEN)Inflammation (via NF-κB and innate immune signaling)Other
05
Safety considerations
No defined drug safety concerns specifically for RNF11 inhibition or activation, since it is not currently a pharmacological drug target. Theoretically, interfering with RNF11 could broadly affect protein turnover, cell signaling, and inflammation, with concerns for immune dysregulation or altered tumorigenesis given its role in NF-κB and TGF-β pathways
06
Biomarkers
No clinically established biomarkers for patient selection or efficacy monitoring based solely on RNF11 at present, though RNF11 overexpression may be a biomarker for certain cancers or inflammation-associated pathologies in research.
Beyond the preview
Go deeper on Ring finger protein 11 (RNF11).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ring finger protein 11 (RNF11).